NeuroVive Pharmaceutical ABの浮動株式数

NeuroVive Pharmaceutical ABの浮動株式数は何ですか。

NeuroVive Pharmaceutical ABの浮動株式数は272.606M 67.64%です。

浮動株式数の定義は何ですか。

浮動株式数は、ロックインされた株式とは対照的に、公的投資家の手にある企業の株式の一部です。

Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded

The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.

OTCのセクタHealth Careにおける浮動株式数の企業と比べるNeuroVive Pharmaceutical AB

NeuroVive Pharmaceutical ABは何をしますか。

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

NeuroVive Pharmaceutical ABと類似の浮動株式数